Indeed, in melanoma patients treated with anti-CTLA4 antibody, NSCLC patients receiving anti-PD1 antibodies and urothelial carcinoma patients receiving anti-PD-L1 therapy, the extent of DNA damage (that corresponds to tumor mutational burden and neoantigen load) correlates with therapeutic response (172–174). This evidence concerns the gene CD274 and neoplasm.